A Randomized Study Evaluating Oral Fusidic Acid (CEM-102) in Combination With Oral Rifampin Compared With Standard-of-Care Antibiotics for Treatment of Prosthetic Joint Infections: A Newly Identified Drug–Drug Interaction

Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014

(2016) David J. Farrell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Outcome of Debridement and Retention in Prosthetic Joint Infections by Methicillin-Resistant Staphylococci, with Special Reference to Rifampin and Fusidic Acid Combination Therapy

(2012) T. N. Peel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of America

(2012) D. R. Osmon et al.   CLINICAL INFECTIOUS DISEASES

Ribosome clearance by FusB-type proteins mediates resistance to the antibiotic fusidic acid

(2012) G. Cox et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pharmacokinetics and Safety of Single, Multiple, and Loading Doses of Fusidic Acid in Healthy Subjects

(2011) J. G. Still et al.   CLINICAL INFECTIOUS DISEASES

In Vitro Antimicrobial Findings for Fusidic Acid Tested Against Contemporary (2008–2009) Gram-Positive Organisms Collected in the United States

(2011) Ronald N. Jones et al.   CLINICAL INFECTIOUS DISEASES

Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102)

(2010) Douglas J. Biedenbach et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Risk factors for treatment failure in orthopedic device-related methicillin-resistant Staphylococcus aureus infection

(2009) T. Ferry et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES